Transcatheter patent ductus arteriosus closure: what have we learned after over 25 years? A single-­center experience with 1036 patients

• DOI: 10.33963/kp.15812
• Publication Date: 2021-02-16T17:12:16Z
• Authors: Michał Gałeczka; Małgorzata Szkutnik; Jacek Białkowski; Linda Litwin; Sebastian Smerdzi...; Mateusz Knop; Jan Głowacki; Roland Fiszer
• Keywords: Ductus arteriosus; Single Center; Cardiac catheterization

Background: Transcatheter patent ductus arteriosus (PDA) closure has become the first‑choice method of treatment in majority patients. However, device selection poses a challenge. Aims: This study aimed to analyze periprocedural and 1‑year outcomes PDA transcatheter performed with different devices throughout 25‑year time period single center. Methods: All 1036 patients who underwent between 1993 2020 were included retrospective analysis. Various used: Rashkind (RD; n = 25), coils (n 469), nitinol duct occluders type I (DO I; 300), II 32), additional sizes (ADO AS; 209), as well off‑label devices: vascular plugs atrial septal muscular ventricular defect 17). Data on 24‑hour follow‑up available for 100% 78.9% patients, respectively. Results: The procedure was successful 98.6% major complication rate 0.2%. Complete after year observed 81.8% treated RD, 93.7% those coils, occluders. There no differences Amplatzer DO 159) its copies manufactured China 141) regard success, efficacy, rates. Recently, ADO AS replaced preferred close small‑to‑moderate PDA. Conclusions: all types is safe effective, residual shunting at follow‑up. Due higher smaller